大麻醇增强了埃托波在前列腺癌细胞上的抗癌活性
Yalcin Erzurumlu1,2, Deniz Catakli3
1Department of Biochemistry, Faculty of Pharmacy, Suleyman Demirel University, Isparta, Türkiye.
Cannabis and cannabinoid research
|August 20, 2024
概括
大麻醇 (CBD) 增强了埃托波西德.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 由于耐药性和副作用,前列腺癌存在重大治疗挑战.
- 大麻三草提取物,特别是大麻二醇 (CBD),正在因其在癌症支持性治疗中的潜力而受到探索.
- 现有的化疗,如埃托波,在前列腺癌治疗中面临有效性的局限.
研究的目的:
- 为了研究大麻 (CBD) 对前列腺癌细胞中的化疗剂埃托波西德的增强作用.
- 为了评估CBD和etoposide对各种癌细胞机制和特性的联合作用.
主要方法:
- 评估了细胞毒性影响,形态变化,亡,自,未折叠蛋白质反应 (UPR) 和与ER相关的降解 (ERAD).
- 检查了对血管性 (VEGF-A) 和雄激素因子,上皮细胞-介质细胞过渡 (EMT) 和细胞衰老的影响.
- 评估了联合治疗对殖民地形成,迁移,入侵和3D瘤发展的影响.
主要成果:
- 通过抑制自和诱导LNCaP细胞中的ERAD和UPR信号,CBD增强了etoposide的抗癌活性.
- 同时治疗显著降低了雄激素信号,VEGF-A,c-Myc和EMT,同时通过caspase-3和PARP-1激活促进了细胞亡.
- 结合CBD和埃托化物显著降低了瘤特性,包括增殖,殖民地生长,迁移,3D形成和诱导衰老.
结论:
- 大麻二醇 (CBD) 显示出对前列腺癌细胞中埃托波西德的抗癌活性有强烈的增强作用.
- CBD可能与现有的化疗方法结合使用,作为一个有前途的辅助疗法.
- 需要进一步的大规模研究来证实CBD作为辅助癌症治疗的临床有效性.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
205
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
205
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
